VSTM · Verastem Oncology
AI read · Good for VSTM
The AI's read
Growing use of the drug combination and added cash give Verastem more room to advance its cancer studies. The royalty deal offers up to $75 million, with $50 million expected at closing, and Secura Bio paid a $15 million milestone. The goal of covering costs with sales by year-end 2026 is still a target, but the sales rebound and added cash support the more favorable read.